Inactive Instrument

News Immunoprecise Antibodies Ltd Other OTC

Equities

CA87588T1030

Summary

Unlock all the news: Be the first to know and act before the market!

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer	06-27	BU
ImmunoPrecise Antibodies Ltd. Appoints Kristin Taylor as Permanent Chief Financial Officer	06-27	CI
IPA's Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai	06-26	AQ
ImmunoPrecise Antibodies Unit, PGxAI to Develop AI Model to Predict Treatment Responses	06-25	MT
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™	06-25	BU
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai Technology	06-13	AQ
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology	06-12	BU
Immunoprecise Antibodies Ltd. Announces the Commercial Release of Lens Ai API, Hereafter Referred to as the `Software', by Its Subsidiary, Biostrand	06-10	CI
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery	06-10	BU
IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model for Electronic Health Records	06-05	AQ
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)	06-04	BU
ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform	04-22	CI
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments	04-12	CI
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications	03-28	BU
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments	03-20	BU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024	03-15	AQ
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024	03-14
ImmunoPrecise Antibodies : Q3 2024 Earnings Presentation	03-14	PU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*	03-14	BU
IMMUNOPRECISE ANTIBODIES : MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 - Form 6-K	03-14	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immunoprecise Antibodies Ltd Other OTC

Equities

CA87588T1030

Summary

Filters